glp-1 drugs for type 2 diabetes Comparing Ozempic, Wegovy and Other Dual GIP/GLP-1 receptor agonists: New

Diabetes Metab Syndr 14(4):289292

Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

M.De CataP.et al (2014)

In the interim, the supply-demand imbalance in high-purity GLP-1 peptide CDMO capacity is giving existing capacity holders unprecedented pricing power and making multi-year capacity reservation agreements with take-or-pay clauses the standard commercial structure for late-stage peptide programmes

Cardiologists will need to counsel patients through that and acclimate them to giving these drugs by subcutaneous injection. Meanwhile, he adds, future research is needed to address whether semaglutide exerts the same protective effects for primary prevention of cardiovascular disease in high-risk individuals with overweight or obesity